You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The drug, Amelie, will be for the second-line treatment of EGFR T790-mutated non-small cell lung cancer.
The study suggested that ALL glucocorticoid resistance stemming from alterations that drive down CELSR2 levels might be combated with the BCL2-targeting drug venetoclax.
Researchers performed single-cell RNA sequencing and demonstrated that the emerging heterogeneity in SCLC necessitates optimal combination treatment strategies at the outset.
BBT-176, a novel agent designed to inhibit EGFR with C797S mutations, will start first-in-human studies in NSCLC this year.
Using corrected TMB and other variables allowed Johns Hopkins researchers to more accurately predict response to immune checkpoint blockade in lung cancer.
The drug is designed to tackle C797S resistance mutations that arise in NSCLC patients after treatment with third-generation tyrosine kinase inhibitors.
Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.
A new study suggests that colorectal cancers increase their mutation rate to dodge treatment in a manner that mirrors microbial resistance mechanisms.
A modified analogue of rucaparib is being used to track PARP-1 expression in PARP inhibitor-treated patients with pancreatic, breast, prostate, and other cancer types.
Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.